Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;37(3):e2822.
doi: 10.1002/hup.2822. Epub 2021 Oct 23.

How prevalent and severe is addiction on GABAmimetic drugs in an elderly German general hospital population? Focus on gabapentinoids, benzodiazepines, and z-hypnotic drugs

Udo Bonnet  1   2 , Heath B McAnally  3   4
Affiliations

How prevalent and severe is addiction on GABAmimetic drugs in an elderly German general hospital population? Focus on gabapentinoids, benzodiazepines, and z-hypnotic drugs

Udo Bonnet et al. Hum Psychopharmacol. 2022 May.

Abstract

Objective: Gabapentinoids (GPT) are reported to be increasingly misused by opioid- and polydrug-users, but the addictive potential of GPT outside of these populations remains understudied. Investigations comparing GPT abuse and dependence liability to that of other commonly prescribed Central Nervous System-acting medications are therefore warranted. We provide a comparison of GPT-abuse/dependence to that of other GABAmimetics within an elderly population.

Design: DSM-IV-TR-based data (previously prospectively collected by SKID-I-interview) from a random sample of elderly patients admitted to a metropolitan German general hospital were reviewed. The prevalence and severity of GPT, benzodiazepine (BDZ), and z-hypnotic drug (ZD)-abuse and -dependence were compared, stratified also by mono-substance (no concurrent current or previous substance use) and de novo-substance (first)-abuse and -dependence states.

Results: Among 400 patients (75 ± 6.4 years old; 63% females), neither current nor past abuse of BDZ, ZD or GPT, nor other illicit substances was observed. Dependence upon BDZ, ZD or GPT was observed among 55 (13.75%) individuals. The related lifetime/12-month prevalence-rates were: dependence condition (BDZ: 7%/2.45%; ZD: 4.25%/4.25%; GPT: 2.75/2.5%); mono-dependence condition (BDZ: 2.25%/0.75%; ZD: 1%/1%, GPT: 0%/0%); de novo-dependence condition (BDZ: 2.75%/1.75%; ZD: 1%/1%, GPT: 0.5%/0.5%). Opioid analgesic-dependence (N = 43/400) was significantly more frequently linked with BDZ than with GPT (p < 0.01) [Correction added on 29 December 2021, after first online publication: In the sentence 'Opioid analgesic-dependence…', the term 'and ZD' has been deleted]. For all three GABAmimetic classes, most mono- and de novo-dependence states were mild-to-moderate and lasted 2-6 years (median).

Conclusion: GABAmimetic-dependence was usually mixed with other substance-dependences. Every third to fourth instance of BDZ- or ZD-dependence was a mono-dependence condition, while a pure GPT-dependence was absent in this elderly (and illicit substance-naïve) population.

Keywords: addiction; gabapentin; heroin; opioid; polydrug use; pregabalin.

PubMed Disclaimer

References

REFERENCES

    1. Abrahamsson, T., Berge, J., Öjehagen, A., & Håkansson, A. (2017). Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study. Drug and Alcohol Dependence, 174, 58-64.
    1. Ahmed, S., Bachu, R., Kotapati, P., Adnan, M., Ahmed, R., Farooq, U., Saeed, H., Khan, A. M., Zubair, A., Qamar, I., & Begum, G. (2019). Use of gabapentin in the treatment of substance use and psychiatric disorders: A systematic review. Frontiers in Psychiatry, 10, 228.
    1. Althobaiti, Y. S., Alghorabi, A., Alshehri, F. S., Baothman, B., Almalki, A. H., Alsaab, H. O., Alsanie, W., Gaber, A., Almalki, H., Alghamdi, A. S., Basfer, A., Althobaiti, S., Hardy, A. M. G., & Shah, Z. A. (2020). Gabapentin-induced drug-seeking-like behavior: A potential role for the dopaminergic system. Scientific Reports, 10(1), 10445.
    1. American Psychiatric Association (APA). (2000). Diagnostic and statistical manual of mental disorders (4th ed., Text Revision (DSM-IV-TR)).
    1. Atkin, T., Comai, S., & Gobbi, G. (2018). Drugs for insomnia beyond benzodiazepines: Pharmacology, clinical applications, and discovery. Pharmacological Reviews, 70(2), 197-245.

Publication types

LinkOut - more resources